Alternatives to Dihexa
Dihexa's preclinical synaptogenic data is striking, but several factors push researchers toward alternatives — the absence of human trials, the theoretical c-Met-pathway safety concerns, the lack of long-term toxicology, and the limited supply through reputable channels. Four realistic substitutes are covered below.
Why look elsewhere
When Dihexa isn't the right fit
The safety questions around chronic c-Met agonism are meaningful and unanswered. No human trials of Dihexa are publicly registered. No long-term animal toxicology data is available. Research designs that involve sustained exposure rather than short-duration mechanistic probing will eventually run into the safety-evidence gap and need a more characterised alternative.
The other reason is supply. Dihexa is available through fewer reputable research-chemical suppliers than Semax or Cerebrolysin, and batch-to-batch variation is harder to verify. For a research design that requires reproducible material across extended timescales, a more standardised alternative is often preferred even if the mechanistic specificity is lower.
The substitutes
Four realistic alternatives
FGL Peptide
NeurogenesisA 15-amino-acid peptide mimetic of the FGL loop of the neural cell adhesion molecule (NCAM), studied for neurogenic, synaptogenic, and memory-enhancing effects in cellular and animal research.
When to choose this instead: Other synaptogenic peptide acting through FGFR1 rather than c-Met. Different pathway, same downstream PI3K-Akt and MAPK signalling, comparable preclinical synaptogenic profile in published research. The theoretical oncogenic-pathway concerns apply to FGFR1 too, but the pathway is distinct enough to be informative as a separate research tool.
Full FGL Peptide profile →Cerebrolysin
NeuroprotectionA complex mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue, studied extensively in cognitive decline and post-stroke recovery research.
When to choose this instead: Multi-component neurotrophic preparation with substantial clinical evidence base, including cognitive recovery data. The synaptogenic effects are diffuse rather than focused (no single defined molecular mechanism) but the human clinical-trial record is the strongest in the cluster. Parenteral route required.
Full Cerebrolysin profile →Semax
Cognitive EnhancementA synthetic heptapeptide analogue of ACTH(4-10) developed in Russia for cognitive enhancement, neuroprotection, and stroke recovery research.
When to choose this instead: BDNF/NGF inducer rather than direct synaptogenic agent — different mechanism but overlapping cognitive endpoint. Choose when the actual research interest is the downstream cognitive enhancement rather than the specific synaptogenic mechanism, or when human safety data depth is non-negotiable.
Full Semax profile →Noopept (Peptide Note)
Cognitive EnhancementA small proline-containing dipeptide derivative — technically a peptidomimetic — developed in Russia as an orally active cognitive enhancer with structural lineage to piracetam.
When to choose this instead: Oral peptidomimetic with BDNF induction and glutamatergic modulation. The mechanism is upstream of synaptogenesis rather than direct. Choose when oral administration is operationally required and the research endpoint can tolerate the less mechanistically focused approach.
Full Noopept (Peptide Note) profile →When NOT to switch
Reasons to stay with Dihexa
Dihexa remains the right choice when the research question is specifically about c-Met pathway agonism as a tool for studying synaptogenesis, when the published preclinical data on dendritic-spine formation at picomolar concentrations is the endpoint of interest, and when oral bioavailability of a synaptogenic agent matters for the protocol design. For mechanistic studies in cell culture and hippocampal slice preparations, the substitutes do not provide the same focused pharmacology.